Alzheimer's Disease Clinical Trials in San Antonio

Showing 61-80 of 91 trials

Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder

NCT02871427

This study seeks to evaluate the long-term safety and effectiveness of nelotanserin for the treatment of visual hallucinations (VHs) and Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD) in subjects with Lewy body dementia (LBD).

Lewy Body DementiaDementia With Lewy BodiesParkinson's Disease Dementia+2 more

Axovant Sciences Ltd.80 participantsStarted Oct 2016

Birmingham, Alabama, United States • Little Rock, Arkansas, United States • Boca Raton, Florida, United States +16 more locations

TERMINATEDPHASE3< 1 mile

Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025

NCT02004392

This is a 26-week, randomized extension of the Phase 3 double-blind placebo-controlled studies, EVP-6124-024 and EVP-6124-025. In this extension study, subjects who complete study EVP-6124-024 or EVP-6124-025 and fulfill all entry criteria will be randomized to receive EVP-6124 for an additional 26 weeks.

Alzheimer's DiseaseDementia

FORUM Pharmaceuticals Inc348 participantsStarted Jun 2014

Phoenix, Arizona, United States • Tucson, Arizona, United States • Little Rock, Arkansas, United States +83 more locations

Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder

Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025

Alzheimer's Disease Trials in Other Cities

Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment

Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and Controls

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)

Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease

Treatment for Aggression and Agitation in Patients With Alzheimer's Disease

Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease

A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease

Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil

Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study

A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease

Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease

Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.

Effect of NeuroAD on the Cognitive Function of Alzheimer Patients

A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Other Conditions in San Antonio